Jennie T. Chang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jennie T. Chang has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Lanh Green
2 shared publicationsJudy A. Staffa
1 shared publicationJulie Beitz
1 shared publicationMary Parks
Division of Metabolic and Endocrine Drug Products, Food and Drug Administration, Rockville, MD, USA
1 shared publication
Latest Publications
- 24 May 2004
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 13 (7) , 417-426
Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
Context: Elevated total cholesterol (total‐C) and low‐density lipoprotein cholesterol (LDL‐C) levels are established risk factors for cardiovascular disease (CVD). HMG‐CoA reductase inhibitors (statins) are effective cholesterol‐lowering drugs that are commonly prescribed to treat this condition. These drugs are often combined with another class of drugs, fibric acid derivatives, to lower both cholesterol and triglyceride levels. Rhabdomyolysis is a known, rare serious side effect of statin monotherapy and of statin‐fibrate combination therapy.Objective: To examine Food and Drug Administration's (FDA's) postmarketing database for cases of rhabdomyolysis in relation to monotherapy and combination use and calculate reporting rates for this event.Design: Domestic cases of statin‐ and statin/gemfibrozil‐associated rhabdomyolysis were culled from FDA's database and reviewed. Rhabdomyolysis was defined by CPK ≥ 10 000 IU/L, myopathic signs and symptoms and clinical diagnosis of rhabdomyolysis. Reporting rates, consisting of number of reported cases/number of prescriptions for each drug, were then calculated to determine whether the reporting of rhabdomyolysis cases was commensurate with extent of use of each statin in the population.Setting: Cases were obtained from the FDA adverse event reporting system (AERS) database.Patients: NA.Main Outcome Measures: Number of rhabdomyolysis cases were evaluated, along with outcomes, such as renal failure, dialysis and death.Results: Of 866 total reported cases, 482 (56%) were associated with monotherapy and 384 (44%) related to combination therapy. More than 80% of reported cases for each drug resulted in hospitalization for renal failure and dialysis. 80 patients expired from events related directly to rhabdomyolysis. Reporting rates for all statins, except for cerivastatin, were similar and much lower than 1 per 100 000 prescriptions. The cerivastatin‐reporting rate was much higher at 4.24/100 000 prescriptions.Conclusions: Rhabdomyolysis is a rare, serious side effect of statin monotherapy and of statin‐fibrate combination therapy. Clinicians need to remain cognizant of this potential adverse event and discuss signs and symptoms of muscle toxicity with patients in order improve the benefits‐to‐risks of treating dyslipidemia with statins. Copyright © 2004 John Wiley & Sons, Ltd.
- 24 May 2004
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 13 (7) , 417-426
Rhabdomyolysis with HMG‐CoA reductase inhibitors and gemfibrozil combination therapy
Context: Elevated total cholesterol (total‐C) and low‐density lipoprotein cholesterol (LDL‐C) levels are established risk factors for cardiovascular disease (CVD). HMG‐CoA reductase inhibitors (statins) are effective cholesterol‐lowering drugs that are commonly prescribed to treat this condition. These drugs are often combined with another class of drugs, fibric acid derivatives, to lower both cholesterol and triglyceride levels. Rhabdomyolysis is a known, rare serious side effect of statin monotherapy and of statin‐fibrate combination therapy.Objective: To examine Food and Drug Administration's (FDA's) postmarketing database for cases of rhabdomyolysis in relation to monotherapy and combination use and calculate reporting rates for this event.Design: Domestic cases of statin‐ and statin/gemfibrozil‐associated rhabdomyolysis were culled from FDA's database and reviewed. Rhabdomyolysis was defined by CPK ≥ 10 000 IU/L, myopathic signs and symptoms and clinical diagnosis of rhabdomyolysis. Reporting rates, consisting of number of reported cases/number of prescriptions for each drug, were then calculated to determine whether the reporting of rhabdomyolysis cases was commensurate with extent of use of each statin in the population.Setting: Cases were obtained from the FDA adverse event reporting system (AERS) database.Patients: NA.Main Outcome Measures: Number of rhabdomyolysis cases were evaluated, along with outcomes, such as renal failure, dialysis and death.Results: Of 866 total reported cases, 482 (56%) were associated with monotherapy and 384 (44%) related to combination therapy. More than 80% of reported cases for each drug resulted in hospitalization for renal failure and dialysis. 80 patients expired from events related directly to rhabdomyolysis. Reporting rates for all statins, except for cerivastatin, were similar and much lower than 1 per 100 000 prescriptions. The cerivastatin‐reporting rate was much higher at 4.24/100 000 prescriptions.Conclusions: Rhabdomyolysis is a rare, serious side effect of statin monotherapy and of statin‐fibrate combination therapy. Clinicians need to remain cognizant of this potential adverse event and discuss signs and symptoms of muscle toxicity with patients in order improve the benefits‐to‐risks of treating dyslipidemia with statins. Copyright © 2004 John Wiley & Sons, Ltd.
- 23 October 2003
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 349 (17) , 1676-1679
Renal Failure with the Use of Zoledronic Acid
Zoledronic acid (Zometa, Novartis Pharmaceuticals) is a potent bisphosphonate that inhibits bone resorption. In trials of treatment for bone metastases, 9 to 15 percent of the patients who received 4 mg of zoledronic acid over a 15-minute period had renal deterioration, defined by elevations in the serum creatinine level.1,2 With marketed use of the drug, renal deterioration progressing to renal failure and dialysis has been reported. Although the causes of renal deterioration are multifactorial, acute tubular necrosis has been described as a potential mechanism associated with zoledronic acid.3
- 23 October 2003
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 349 (17) , 1676-1679
Renal Failure with the Use of Zoledronic Acid
Zoledronic acid (Zometa, Novartis Pharmaceuticals) is a potent bisphosphonate that inhibits bone resorption. In trials of treatment for bone metastases, 9 to 15 percent of the patients who received 4 mg of zoledronic acid over a 15-minute period had renal deterioration, defined by elevations in the serum creatinine level.1,2 With marketed use of the drug, renal deterioration progressing to renal failure and dialysis has been reported. Although the causes of renal deterioration are multifactorial, acute tubular necrosis has been described as a potential mechanism associated with zoledronic acid.3